Ohios Drug-Pricing Ballot Question Triggers Voter Confusion
Millions of dollars in campaign spending and a media blitz of advertisements muddy public understanding of Issue 2, the Drug Price Relief Act.
Drugs
1,061 - 1,080 of 1,288 Results
-
-
Liquid Gold: Pain Doctors Soak Up Profits By Screening Urine For Drugs
With the nation's opioid crisis, urine testing has become a booming business and is especially lucrative for doctors who operate their own labs, a Kaiser Health News investigation finds. And dozens of practitioners have earned "the lions share" of their Medicare income exclusively from urine drug screens.
By Fred Schulte and Elizabeth Lucas -
Health Companies Race To Catch UnitedHealth As Amazon Laces Up
UnitedHealth, a health industry goliath, has its hand in doctors offices, surgery centers, technology services and prescription drugs. It is the industry model, and CVS and Aetna, says one expert, are wannabes.
By Chad Terhune -
House Republicans Aim To Yank Tax Credits For Orphan Drugs
House Republicans want to repeal federal tax credits that have helped spur a boom in orphan drugs for rare diseases.
-
Timeline: Insulin Market Under Scrutiny
A flurry of federal and state probes have targeted insulin manufacturers and pharmacy benefit managers middlemen in the prescription drug-pricing pipeline. Here, we connect the legal dots.
-
Flurry Of Federal And State Probes Target Insulin Drugmakers And Pharma Middlemen
Over the past two years, a powerful federal prosecutor and several state attorneys general have launched investigations related to diabetes drugs.
-
Desperate Quest For Herpes Cure Launched Rogue Trial
Patients flocked to researcher who ignored usual patient protections, as university claimed ignorance.
-
Cascade of Costs Could Push New Gene Therapy Above $1 Million Per Patient
The costs of using a new class of cancer treatments include far more than the drugs sticker price.
By Liz Szabo -
New Law Challenges ‘Evils’ Of Pharma Profits, California Governor Claims
Gov. Jerry Brown signed the measure, which takes effect next year and will require drug companies to publicly justify big price increases.
-
Eyes Fixed On California As Governor Ponders Inking Drug Price Transparency Bill
"If it gets signed by this governor, it's going to send shock waves throughout the country, one legislator says. Pharma has spent $16.8 million lobbying against this bill and other drug laws in California.
-
Hepatitis C Drugs Lower Cost Paves Way For Medicaid, Prisons To Expand Treatment
The drug, sold under the name Mavyret, can cure all six genetic types of the liver disease in eight weeks at a cost of $26,400, well below other options.
-
Do Pharma’s Claims On Drug Prices Pass The Smell Test? We Found 5 Stinkers.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
By Jay Hancock -
Absent Federal Action, States Take The Lead On Curbing Drug Costs
Congress has yet to take substantive action on this growing consumer concern, but a number of states are flexing their cost-control muscle.
-
Out-Of-Pocket Costs Often Keep Pricey New Cholesterol Drugs Out Of Reach, Study Finds
Research published this week by JAMA Cardiology analyzed pharmacy claims data related to a new class of cholesterol-lowering drugs.
-
Right After Trump Blamed High Drug Prices On Campaign Cash, Drugmakers Gave More
At a political rally in March, President Donald Trump said drug prices are outrageous and blamed campaign contributions. Drugmakers funneled nearly $280,000 to Congress the very next day.
By Sydney Lupkin and Elizabeth Lucas -
News Analysis
Everyone Says We Must Control Exorbitant Drug Prices. So, Why Dont We?
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
By Jay Hancock -
High On Drugs? Anthem Cites Soaring Drug Costs To Justify 35% Rate Hike in California
The companys drug spending prediction, far above other insurers in the individual market, has experts scratching their heads. Anthem cites market volatility.
泭By Chad Terhune -
The Orphan Drug Machine
Without Price Breaks, Rural Hospitals Struggle To Stock Costly, Lifesaving Drugs
A federal drug program blocks rural hospitals from getting discounts on rare-disease drugs, forcing staff to cut back on supplies of lifesaving medicines.
-
The Orphan Drug Machine
FDA Moves To Guard Against Abuse Of Orphan Drug Program
Following a KHN investigation, the Food and Drug Administration has moved to speed up approvals of orphan drugs while closing a loophole that allowed drugmakers to skip pediatric testing.
-
Meningitis B Vaccines High Price Poses A Health Care Conundrum For College-Bound
This immunization may mark a shift among some vaccine makers to higher-priced, niche preventives that protect against very specific and sometimes rare illnesses.